검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Abraxane + carboplatin (Abraxane + carboplatin) AstraZeneca·Non Small Cell Lung Cancer NSCLC ORR 44.9% |
|---|---|
Overview Program | Abraxane + carboplatin |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Non Small Cell Lung Cancer NSCLC |
Overview Indication | Non Small Cell Lung Cancer NSCLC |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting the ERRα/LDHA pathway |
MoA Biomarker | biomarkers to guide patient selection and treatment adaptation are lacking |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer.. In locally advanced head and neck squamous cell carcinoma (HNSCC), rapid tumor progression during the preoperative waiting period is a critical concern. This study evaluated the clinical and pathological responses to neoadjuvant paclitaxel, carboplatin, and cetuximab (PCE) therapy used … |
Clinical Primary efficacy | ORR 44.9% |
Clinical ORR | 44.9% |
Clinical PFS | 49.0 |
Clinical OS | 298 |
Clinical Result source | ClinicalTrials.gov NCT01317615 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Abraxane + carboplatin (Abraxane + carboplatin) AstraZeneca·Non Small Cell Lung Cancer NSCLC ORR 44.9% |
|---|---|
Overview Program | Abraxane + carboplatin |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Non Small Cell Lung Cancer NSCLC |
Overview Indication | Non Small Cell Lung Cancer NSCLC |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting the ERRα/LDHA pathway |
MoA Biomarker | biomarkers to guide patient selection and treatment adaptation are lacking |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer.. In locally advanced head and neck squamous cell carcinoma (HNSCC), rapid tumor progression during the preoperative waiting period is a critical concern. This study evaluated the clinical and pathological responses to neoadjuvant paclitaxel, carboplatin, and cetuximab (PCE) therapy used … |
Clinical Primary efficacy | ORR 44.9% |
Clinical ORR | 44.9% |
Clinical PFS | 49.0 |
Clinical OS | 298 |
Clinical Result source | ClinicalTrials.gov NCT01317615 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교